Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5

Journal of Clinical Microbiology

Volumn 44, Issue 3, 2006, Pages 729-737

  Sarrazin, Christoph ^a   Gärtner, Barbara C ^a   Sizmann, Dorothea ^b   Babiel, Rainer ^b   Mihm, Ulrike ^a   Hofmann, Wolf Peter ^a   Von Wagner, Michael ^a   Zeuzem, Stefan ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; DNA DETERMINATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; INTERMETHOD COMPARISON; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS;

DNA, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

HEPATITIS C VIRUS;

EID: 33644889424     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.44.3.729-737.2006     Document Type: Article

References (32)

1. Afdhal, N., E. Godofsky, J. Dienstag, V. Rustgi, L. Schick, D. McEniry, X. J. Zhou, G. Chao, C. Fang, B. Fielman, M. Myers, and N. Brown. 2004. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 40(Suppl. 1):726A.
2. Beld, M., R. Sentjens, S. Rebers, C. Weegink, J. Weel, C. Sol, and R. Boom. 2002. Performance of the new Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, version 2.0, assay. J. Clin. Microbiol. 40:788-793.
3. Berg, T., C. Sarrazin, E. Hermann, H. Hinrichsen, T. Gerlach, R. Zachoval, B. Wiedenmann, U. Hopf, and S. Zeuzem. 2003. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37:600-609.
4. Dalgard, O., K. Bjoro, K. B. Hellum, B. Myrvang, S. Ritland, K. Skaug, N. Raknerud, and H. Bell. 2004. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40:1260-1265.
5. Davis, G. L., J. B. Wong, J. G. McHutchison, M. P. Manns, J. Harvey, and J. Albrecht. 2003. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38:645-652.
6. Davis, G. L. 2002. Monitoring of viral levels during therapy of hepatitis C. Hepatology 36:5145-5151.
7. Elbeik, T., J. Surtihadi, M. Destree, J. Gorlin, M. Holodniy, S. A. Jortani, K. Kuramoto, V. Ng, R. Valdes, Jr., A. Valsamakis, and N. A. Terrault. 2004. Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J. Clin. Microbiol. 42:563-569.
8. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Gonzales, D. Häussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffmann, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
9. Gerken, G., T. Rothaar, M. G. Rumi, R. Soffredini, M. Trippler, M. J. Blunk, A. Butcher, S. Soviero, and G. Colucci. 2000. Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J. Clin. Microbiol. 38:2210-2214.
10. Germer, J. J., W. S. Harmsen, J. N. Mandrekar, P. S. Mitchell, and J. D. Yao. 2005. Evaluation of the COBAS TaqMan HCV test with automated sample processing using the MagNA pure LC instrument. J. Clin. Microbiol. 43:293-298.
11. Germer, J. J., P. J. Heimgartner, D. M. Ilstrup, W. S. Harmsen, G. D. Jenkins, and R. Patel. 2002. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40:495-500.
12. Hadziyannis, S. J., H. Sette, Jr., T. R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. C. Bodenheimer, Jr., D. Bernstein, M. Rizzetto, S. Zeuzem, P. J. Pockros, A. Lin, and A. M. Ackrill. 2004. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355.
13. Herrmann, E., A. U. Neumann, J. M. Schmidt, and S. Zeuzem. 2000. Hepatitis C virus kinetics. Antivir. Ther. 5:85-90.
14. Hinrichsen, H., Y. Benhamou, H. Wedemeyer, M. Reiser, R. E. Sentjens. J. L. Calleja, X. Forns, A. Erhardt, J. Cronlein, R. L. Chaves, C. L. Yong, G. Nehmiz, and G. G. Steinmann. 2004. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127:1347-1355.
15. Konnick, E. Q., S. M. Williams, E. R. Ashwood, and D. R. Hillyard. 2005. Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan analyte-specific reagent assay and comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 assays. J. Clin. Microbiol. 43:2133-2140.
16. Layden, J. E., T. J. Layden, K. R. Reddy, R. S. Levy-Drummer, J. Poulakos, and A. U. Neumann. 2002. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J. Viral Hepat. 9:340-345.
17. Lee, S. C., A. Antony, N. Lee, J. Leibow, J. Q. Yang, S. Soviero, K. Gutekunst, and M. Rosenstraus. 2000. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J. Clin. Microbiol. 38:4171-4179.
18. Mangia, A., R. Santoro, N. Minerva, G. L. Ricci, V. Carretta, M. Persico, F. Vinelli, G. Scotto, D. Bacca, M. Annese, M. Romano, F. Zechini, F. Sogari, F. Spirito, and A. Andriulli. 2005. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352:2609-2617.
19. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
20. Martell, M., J. Gomez, J. I. Esteban, S. Sauleda, J. Quer, B. Cabot, R. Esteban, and J. Guardia. 1999. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J. Clin. Microbiol. 37:327-332.
21. Morishima, C., M. Chung, K. Ng, D. J. Brambilla, and D. R. Gretch. 2004. Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J. Clin. Microbiol. 42:421-425.
22. National Institutes of Health. 2002. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36:S3-S20.
23. Nolte, F. S., M. W. Fried, M. L. Shiffman, A. Ferreira-Gonzalez, C. T. Garrett, E. R. Schiff, S. J. Polyak, and D. R. Gretch. 2001. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J. Clin. Microbiol. 39:4005-4012.
24. Pawlotsky, J. M., M. Bouvier-Alias, C. Hezode, F. Darthuy, J. Remire, and D. Dhumeaux. 2000. Standardization of hepatitis C virus RNA quantification. Hepatology 32:654-659.
25. Reesink, H. W., S. Zeuzem, C. J. Weegink, N. Forestier, A. van Vliet, J. van de Wetering de Rooij, L. McNair, S. Purdy, H.-M. Chu, and P. L. M. Jansen. 2005. Initial results of a phase 1b multiple dose study of VX950, a hepatitis C virus protease inhibitor. Gastroenterology 128(Suppl. 2):527A.
26. Reiser, M., H. Hinrichsen, J. P. Benhamou, H. W. Reesink, H. Wedemeyer, C. Avendano, N. Riba, C. L. Yong, G. Nehmiz, and G. Steinmann. 2005. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41:832-835.
27. Ross, R. S., S. Viazov, S. Sarr, S. Hoffmann, A. Kramer, and M. Roggendorf. 2002. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J. Virol. Methods 101:159-168.
28. Sarrazin, C., B. Gärtner, M. Welker, S. Traver, and S. Zeuzem. 2004. Evaluation of a new, highly sensitive, real time PCR based assay for quantification of HCV RNA. J. Hepatol. 40(Suppl. 1):150A.
29. Simmonds, P., E. C. Holmes, T. A. Cha, F. McOmish, B. Irvine, E. Beall, P. L. Yap, J. Kolberg, and M. S. Urdea. 1993. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74:2391-2399.
30. von Wagner, M., M. Huber, T. Berg, H. Hinrichsen, J. Rasenack, T. Heintges, A. Bergk, C. Bernsmeier, D. Haussinger, E. Herrmann, and S. Zeuzem. 2005. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129:522-527.
31. Zeuzem, S., E. Heirmann, J. H. Lee, J. Fricke, A. U. Neumann, M. Modi, G. Colucci, and W. K. Roth. 2001. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 120:1438-1447.
32. Zeuzem, S., R. Hultcrantz, M. Bourliere, T. Goeser, P. Marcellin, J. Sanchez-Tapias, C. Sarrazin, J. Harvey, C. Brass, and J. Albrecht. 2004. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 40:993-999.